Case Number 7260
Request Date 11/02/2020
Completion Date 04/02/2021

 

Details of the Request

For Rheumatology /Dermatology / Gastroenterology

Is the branded biosimilar AMGEVITA listed on your formulary?

Please complete the number of patients prescribed with the following products in the last 12 months within the Rheumatology, Dermatology and Gastroenterology departments:

Product/place in the adalimumab therapy pathway

  • AMGEVITA first-line
  • AMGEVITA second-line
  • HUMIRA first-line
  • HUMIRA second-line
  • HYRIMOZ first-line
  • IMRALDI first-line

 

How many patients receive the listed therapies as a first or second treatment once they reach the biologic / biosimilar part of their treatment pathway.

Please complete the table below:

 

Rheumtology:

  • Rheumatoid arthritis
  • Ankylosing spondylitis

 

Dermatology:

  • Psoriasis
  • Psoriatic arthritis

 

Gastroenterology

  • Crohn’s disease
  • Ulcerative colitis

 

Are any local guidelines followed that recommend earlier use of anti-TNF biologics / biosimilars in the treatment pathway?

 

Are there occasions where patients can receive adalimumab outside of NICE / SMC / AWMSG / National criteria?

 

What is the contractual agreement for seeing and treating patients with anti-TNF biologics between you and your referring CCGs / Health Boards?

  • Contractual agreement
  • Block contracts

 

Details of the Response

Question 1

  Rheumatology Dermatology Gastroenterology
Is the branded biosimilar AMGEVITA listed on your formulary? Yes No, it will be updated Yes

 

Question 2

Please complete the number of patients prescribed with the following products in the last 12 months within the Rheumatology, Dermatology and Gastroenterology departments:

Product/place in the adalimumab therapy pathway* Rheumatology Dermatology Gastroenterology
AMGEVITA first-line N/A N/A N/A
AMGEVITA second-line 0 0 0
HUMIRA first-line N/A N/A N/A
HUMIRA second-line 101 37 74
HYRIMOZ first-line N/A N/A N/A
IMRALDI first-line 121 7 46

* How many patients receive the listed therapies as a first or second treatment once they reach the biologic/biosimilar part of their treatment pathway. For example, according to the NICE Pathway, psoriasis patients should receive topical therapy, then systemic non-biological therapy, then systemic biological therapy. We would like to know which therapies are received first and second in the biological therapy part of the pathway.

 

Question 3

Are any local guidelines followed that recommend earlier use of anti-TNF biologics/ biosimilars in the treatment pathway?

No

 

Are there occasions where patients can receive adalimumab outside of NICE / SMC / AWMSG / National criteria?

No

 

Question 4

What is the contractual agreement for seeing and treating patients with anti-TNF biologics between you and your referring CCGs / Health Boards?

  • Block contracts = No
  • Fixed price on a patient-by-patient basis = Yes

 

 

Protecting Your Online Privacy
Protecting Your Online Privacy

This Ashford and St Peter's website uses cookies to track visitor numbers. Find out more in our Cookies Policy and Privacy Policy. You can also read our Accessibility Statement and Privacy Notice for your information.